Arix Bioscience plc: Board changes

Arix Bioscience plc: Board changes

LONDON, 28 March 2019: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announced that Mark Breuer has been appointed to the Board of the Company as Non-Executive Director with effect from 25th April 2019. Upon appointment, Mark will become a member of the Audit Committee and of the Nomination Committee. Mark replaces Meghan FitzGerald, who will be stepping down from the Board, with effect from the 1st April 2019.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH